SEC Tracker
Get the app

Equillium EQ

Equillium receives trial approval for EQ504

Form
8-K
Filed
Importance
Routine
  1. Received ethics approval for Phase 1 trial
  2. Trial to start dosing in November 2026
  3. Includes 3 parts: single dose, multiple dose, food effect

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Equillium files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zeo ScientifiX ZEOX public float $7M, Apr 30, 2025, over 18 months old
  2. Sunshine Biopharma SBFM public float $7M, Jun 30, 2025
  3. Neuphoria Therapeutics NEUP public float $7M, Dec 31, 2025
  4. CV Sciences CVSI public float $7M, Jun 30, 2025
  5. Minerva Neurosciences NERV public float $7M, Jun 30, 2025